GDF15 Inhibits PVR Membrane Formation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is no current pharmacologic agent to treat or prevent proliferative vitreoretinopathy (PVR), a complication of rhegmatogenous retinal detachment characterized by the formation of proliferative, contractile cellular membranes that lead to tractional retinal detachment and poor visual outcomes, despite surgical interventions.
Innovation Solution
Administration of an effective dose of Growth Differentiation Factor 15 (GDF15), potentially in combination with other therapeutic agents, to inhibit epithelial-mesenchymal transition (EMT) and reduce proliferation of retinal pigment epithelial cells, thereby addressing the underlying cellular processes contributing to PVR.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If surgical intervention is performed to treat PVR, then anatomical reattachment can be achieved, but visual function recovery remains poor due to formation of contractile membranes and retinal folds
Solution Approach 1:
The patent applies preliminary action by administering GDF15 before surgical intervention to prevent the formation of contractile membranes and epithelial-mesenchymal transition. This pre-treatment approach aims to eliminate the pathological processes that lead to poor visual outcomes, rather than treating them after surgery has already occurred.
Solution Approach 2:
GDF15 serves as a pharmacologic intermediary that mediates between the surgical intervention and the pathological processes of PVR. The agent interferes with the signaling pathways (TGF-β, PDGF, VEGF) that drive membrane formation and contraction, thereby protecting visual function while allowing surgical reattachment to proceed.
2Reliability
If multiple surgical procedures are performed to treat PVR, then anatomical success can be improved, but treatment complexity and patient burden increase significantly
Solution Approach 1:
The patent employs preliminary action by administering GDF15 prior to surgery to prevent the development of complex membrane formations that would require multiple surgical interventions. This approach simplifies the overall treatment protocol by addressing the underlying pathophysiology before it progresses to stages requiring repeated procedures.
3Object-affected harmful factors
If pharmacologic agents are used to inhibit cell proliferation and EMT, then prevention of contractile membrane formation is achieved, but no effective agent has been identified until GDF15
Solution Approach 1:
The patent identifies GDF15 as a novel pharmacologic agent that targets specific molecular parameters in the PVR pathway, including inhibition of epithelial-mesenchymal transition and suppression of contractile protein expression. This represents a new parameter target in PVR therapy, expanding the available therapeutic options beyond surgical intervention.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
GDF15 treatment effectively reduces the severity of PVR by inhibiting Smad2 pathway activation and Fibronectin expression, improving visual acuity, reducing recurrence risk, and enhancing retinal reattachment rates following surgical interventions.
Implementation Method 1
GDF15 treatment effectively reduces the severity of PVR by inhibiting Smad2 pathway activation and Fibronectin expression
Data Source
AI summary
An effective dose of Growth Differentiation Factor 15 (GDF15) is used for prevention or treatment of proliferative vitreoretinopathy. Specifically, the disclosure provides methods and compositions for treatment of proliferative vitreoretinopathy (PVR), which is based on preventing or reducing proliferation, cell migration, or epithelial-mesenchymal transition (EMT) of epithelial cells involved in PVR.